News | February 19, 2026
Zydus introduces ANYRA (Aflibercept 2 mg) for advanced retinal disease treatment
ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar
ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar
The acquisition marks the company’s strategic entry into the fast-growing Hormone Replacement Therapy (HRT) segment and significantly strengthens its gynaecology portfolio in India
The trial targeted a patient population with high BMI and extensive skin involvement, averaging over 39 kg/m²
The approval is based on the SWIFT and ANCHOR phase III trials, which demonstrated sustained efficacy with a twice-yearly dosing regimen
Wegovy is now offered in six weekly doses in the EU: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and the newly approved 7.2 mg dose
BREAKWATER is a Phase 3, randomized, open-label trial testing BRAFTOVI in combination with cetuximab, either alone or with chemotherapy, in patients with untreated BRAF V600E-mutant mCRC
The therapy, also known as UM171 Cell Therapy, recently received conditional marketing authorization from the European Commission
Backed by a multi-hundred-million-dollar investment, the expansion underscores Sanofi’s long-term commitment to India’s thriving life sciences ecosystem
The trial, which compared Retevmo to placebo, met its primary endpoint with a “highly statistically significant and clinically meaningful improvement” in investigator-assessed EFS for patients with stage II–IIIA disease
Primary membranous nephropathy is a chronic autoimmune disease that attacks the kidneys’ filtering units
Subscribe To Our Newsletter & Stay Updated
